(-)-11-nor-9-carboxy-delta9-thc
(-)-11-nor-9-carboxy-delta9-thc structure
|
Common Name | (-)-11-nor-9-carboxy-delta9-thc | ||
|---|---|---|---|---|
| CAS Number | 56354-06-4 | Molecular Weight | 344.445 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 466.9±45.0 °C at 760 mmHg | |
| Molecular Formula | C21H28O4 | Melting Point | 211ºC | |
| MSDS | N/A | Flash Point | 158.1±22.2 °C | |
| Symbol |
GHS02, GHS06, GHS08 |
Signal Word | Danger | |
|
Analysis of 11-nor-Δ9 -tetrahydrocannabinol-9-carboxylic acid and its glucuronide in urine by capillary electrophoresis/mass spectrometry.
Biomed. Chromatogr. 26(11) , 1452-6, (2012) Δ(9) -Tetrahydrocannabinol is the primary psychoactive component in cannabis, one of the most commonly used illicit drugs in the world. This paper describes a simple and rapid method for direct analysis of major metabolites of Δ(9) -tetrahydrocannabinol; 11-n... |
|
|
Drugs of abuse and benzodiazepines in the Madrid Region (Central Spain): seasonal variation in river waters, occurrence in tap water and potential environmental and human risk.
Environ. Int. 70 , 76-87, (2014) This work analyzes the seasonal variation (winter and summer) of ten drugs of abuse, six metabolites and three benzodiazepines in surface waters from the Jarama and Manzanares Rivers in the Madrid Region, the most densely populated area in Spain. The occurren... |
|
|
Cannabinoid disposition in oral fluid after controlled smoked cannabis.
Clin. Chem. 58(4) , 748-56, (2012) We measured Δ(9)-tetrahydrocannabinol (THC), 11-nor-9-carboxy-THC (THCCOOH), cannabidiol (CBD), and cannabinol (CBN) disposition in oral fluid (OF) following controlled cannabis smoking to evaluate whether monitoring multiple cannabinoids in OF improved OF te... |
|
|
Identification of recent cannabis use: whole-blood and plasma free and glucuronidated cannabinoid pharmacokinetics following controlled smoked cannabis administration.
Clin. Chem. 57(10) , 1406-14, (2011) Δ⁹-Tetrahydrocannabinol (THC) is the most frequently observed illicit drug in investigations of accidents and driving under the influence of drugs. THC-glucuronide has been suggested as a marker of recent cannabis use, but there are no blood data following co... |
|
|
On-site test for cannabinoids in oral fluid.
Clin. Chem. 58(10) , 1418-25, (2012) Oral fluid (OF) testing offers noninvasive sample collection for on-site drug testing; however, to date, test performance for Δ(9)-tetrahydrocannabinol (THC) detection has had unacceptable diagnostic sensitivity. On-site tests must accurately identify cannabi... |
|
|
In vitro stability of free and glucuronidated cannabinoids in blood and plasma following controlled smoked cannabis.
Clin. Chem. 59(7) , 1108-17, (2013) Blood and plasma cannabinoid stability is important for test interpretation and is best studied in authentic rather than fortified samples.Low and high blood and plasma pools were created for each of 10 participants after they smoked a cannabis cigarette. The... |
|
|
Distribution of free and conjugated cannabinoids in human bile samples
Forensic Sci. Int. 223(1-3) , 114-8, (2012) The metabolism of Δ9-tetrahydrocannabinol (THC) is relatively complex, and over 80 metabolites have been identified [1]. However, much less is known about the formation and fate of cannabinoid conjugates. Bile excretion is known to be an important route for t... |
|
|
Psychomotor performance, subjective and physiological effects and whole blood Δ⁹-tetrahydrocannabinol concentrations in heavy, chronic cannabis smokers following acute smoked cannabis.
J. Anal. Toxicol. 36(6) , 405-12, (2012) Δ⁹-Tetrahydrocannabinol (THC) is the illicit drug most frequently observed in accident and driving under the influence of drugs investigations. Whole blood is often the only available specimen collected during such investigations, yet few studies have examine... |
|
|
Correlations and agreement between delta-9-tetrahydrocannabinol (THC) in blood plasma and timeline follow-back (TLFB)-assisted self-reported use of cannabis of patients with cannabis use disorder and psychotic illness attending the CapOpus randomized clinical trial.
Addiction 107(6) , 1123-31, (2012) To assess correlations and agreement between timeline follow-back (TLFB)-assisted self-report and blood samples for cannabis use.Secondary analysis of a randomized trial.Copenhagen, Denmark.One hundred and three patients from the CapOpus trial with cannabis u... |
|
|
Single-dose pharmacokinetics and tolerability of oral delta-9- tetrahydrocannabinol in patients with amyotrophic lateral sclerosis.
Drug Metab. Lett. 6(2) , 102-8, (2012) Cannabinoids exert neuroprotective and symptomatic effects in amyotrophic lateral sclerosis (ALS). We assessed the pharmacokinetics (PK) and tolerability of delta-9-tetrahydrocannabinol (THC) in ALS patients.Nine patients received THC single oral doses of 5mg... |